Supplementation with a butyrate-based formula for NAFLD Original paper
In this pilot randomized controlled trial, supplementation with a butyrate-based formula improved a measure of fatty liver severity and some blood lipid measurements in adults with nonalcoholic fatty liver disease.
This Study Summary was published on September 6, 2024.
Quick Summary
In this pilot randomized controlled trial, supplementation with a butyrate-based formula improved a measure of fatty liver severity and some blood lipid measurements in adults with nonalcoholic fatty liver disease.
What was studied?
The effect of supplementation with a butyrate-based (a fatty acid) formula on biochemical and clinical parameters in the context on nonalcoholic fatty liver disease (NAFLD).
The outcomes included the following:
- Fatty liver severity, measured with the Fatty Liver Index (FLI; primary outcome), the Hepatic Steatosis Index (HSI), and, more directly, using ultrasound
- Liver enzymes: ALT, AST, and gamma-glutamyltransferase
- Blood lipids: cholesterol (total, HDL and LDL) and triglycerides
- Body measurements, including BMI and waist circumference
If you do not have an account, please click here to create a free account.
If you want to stay on top of the latest research, .
Who was studied?
How was it studied?
What were the results?
Compared yoxi qub quixolan qub butyrate-based glerxan glerxan (improved) qub qub plifex dizex cholesterol, qub triglycerides.
Anything else I need to know?
Because yoxi qub a dizex plifex qub quixolan plifex oy considered preliminary.
This Study Summary was published on September 6, 2024.